Here we take a look at the top 10 largest pharmaceutical companies dominating the industry to give investors insight.
Dominating the world through pharmaceuticals by leading with the biggest and most well-known drugs, these companies are the big pharmas.
These companies do more than uphold the standard of big pharmas—through massive research and development pipelines and global distribution and sales of its products—the companies also give direction to smaller pharma companies interested in specific treatment areas.
Although the industry faces potential threats such as technology companies making a big impact on healthcare, the pharmaceutical industry is still one of the most profitable industries—especially in the US. Taking a look at these companies also gives investors a good idea often of where the smaller pharma companies are heading and what to look for in a successful company. Mid-way through the second quarter we look at the biggest pharmaceutical companies based on the company’s current market cap.
Here we take a look at the top 10 largest pharmaceutical companies dominating the industry to give investors insight. These companies have all made it to the top spots by developing new medications which have shaped the world, and have earned a spot in the top 10 by selling a variety of stable products. It’s always important to focus attention on these companies because in many ways, they dictate where the pharmaceutical industry is heading. All figures are in US dollars, unless otherwise noted and were taken as of 1 p.m. EST May 29, 2018.
1. Johnson & Johnson (NYSE:JNJ)
Market cap: $319.23 billion; current share price: $119.02
It’s no secret that this company has been a household name for decades. With a market cap over $300 billion—it shouldn’t be a surprise Johnson & Johnson is top on our list. The company is the top in its industry based on consumer healthcare revenue with revenue of $71.89 billion. They’re also the name behind some of the most common American products such as Tylenol, Aveeno, and Bandaid. In Q1 2018 the company’s sales increased 12.6 percent to $20 billion compared to the same quarter in 2017.
2. Pfizer (NYSE:PFE)
Market cap: $207.66 billion; current share price: $35.46
Pfizer works with a range of health products and treatments from therapeutics to technologies impacting drug discovery and development. Pfizer is the brains behind Advil, Emergen-C, and Robax. The company may have only had a one percent growth, or $127 million in revenue from Q1 2017 to Q1 2018,however its drug Trumenba did receive breakthrough therapy designation in the quarter.
3. Roche Holdings (OTCMKTS:RHHBY)
Market cap: $185.27 billion; current share price: $27.14
The Swiss Roche Holdings pharmaceutical division sales grew seven percent in the first quarter of 2018, to $10.67 billion. Also in the first quarter the company had two drug approvals—Ocrevus for forms of MS and Hemlibra for haemophilia A. Being Swiss-based if anything gives the company an advantage to working in the European Union while pioneering global pharmaceuticals, this company has created products in rheumatology, metabolism, oncology and virology among others.
4. Novartis (NYSE:NVS)
Market cap: $168.27 billion; current share price: $74.93
Novartis is another Swiss multinational pharmaceutical company based in Basel, similar to Roche Holdings. Novartis’ Q1 financial results revealed a four percent increase in net sales mainly driven from sales of Entresto, Cosentyx and its oncology area with Promacta/Revolade, Tafinlar and more. Some of the company’s focus are cancer, cardio-metabolic, neuroscience, immunology and dermatology, among others.
5. AbbVie (NYSE:ABBV)
Market cap: $157.23 billion; current share price: $99.08
AbbVie is a global company developing and commercializing advanced therapies and oncology treatments. Compared to Q1 2017 the company’s Q1 2018 worldwide sales increased 21.4 percent to $7.93 billion. This was primarily driven by Humira and Imbruvica sales, which increased 20 percent and 47.2 percent, respectively.
6. Merck (NYSE:MRK)
Market cap: $156.64 billion; current share price: $58.22
Another company also focused on animal health, Merck, first developed vaccines for mumps and rubella. In Q1 2018 the company reported a six percent increase in worldwide sales including a three percent positive impact from foreign exchange. The new product Keytruda had the biggest increase in sales at 151 percent.
7. Abbott Laboratories (NASDAQ:ABT)
Market cap: $106.80 billion; current share price: $60.92
This US-based global healthcare company has a variety of products approved and in development for every space in healthcare including diagnostics, medical devices, and generic pharmaceuticals. For the first quarter 2018 the company had a 16.7 percent increase in global sales totaling to $7.39 billion compared to the first quarter in 2017.
8. Bayer (OTCMKTS:BAYRY)
Market cap: $98.99 billion; current share price: $28.84
This German multinational company is focused on consumer health, animal health, and crop science—the latter explains their $63.5 billion deal with Monsanto, which was approved in the first quarter. The company’s first quarter group sales were €9.13 million which was a 2 percent increase from the same quarter in 2017.
9. GlaxoSmithKline (NYSE:GSK)
Market cap: $98.405 billion; current share price: $39.69
This British company develops a wide range of prescription medicines, vaccines, and commonly known consumer health products such as Voltaren, NeoCitran and Sensodyne. With main growth in pharmaceuticals and consumer healthcare products. GSK’s pharmaceutical sales alone was over £4 billion while vaccine sales were over £1.2 billion during Q1 2018.
10. Sanofi (NYSE:SNY)
Market cap: $94.54 billion; current share price: $37.81
The France-based Sanofi has started the year off by acquiring Bioverativ (NASDAQ:BIVV) for $11.6 billion to enhance their own revenue and earnings growth. Some of the company’s lead products include Dulcolax for digestive health, Selsun Blue for Health and Beauty, and Cliniderm for Cosmeceuticals. For Q1 2018 Sanofi increased net sales 8.3 percent from the previous quarter to €7.89 billion, with the biggest increase from its established Rx products.
This is an updated version of an article originally published on the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Gabrielle Lakusta, hold no investment interest in any of the companies mentioned.